학술논문
Type I interferon autoantibodies in hospitalized patients with Middle East respiratory syndrome and association with outcomes and treatment effect of interferon beta‐1b in MIRACLE clinical trial.
Document Type
Article
Author
Alotaibi, Faizah; Alharbi, Naif Khalaf; Rosen, Lindsey B.; Asiri, Ayed Y.; Assiri, Abdullah M.; Balkhy, Hanan H.; Al Jeraisy, Majed; Mandourah, Yasser; AlJohani, Sameera; Al Harbi, Shmeylan; Jokhdar, Hani A. Aziz; Deeb, Ahmad M.; Memish, Ziad A.; Jose, Jesna; Ghazal, Sameeh; Al Faraj, Sarah; Al Mekhlafi, Ghaleb A.; Sherbeeni, Nisreen Murad; Elzein, Fatehi Elnour; AlMutairi, Badriah M.
Source
Subject
*MIDDLE East respiratory syndrome
*INTERFERON beta 1b
*AUTOANTIBODIES
*HOSPITAL patients
*TYPE I interferons
*TREATMENT effectiveness
*CLINICAL trials
*
*
*
*
*
*
Language
ISSN
1750-2640
Abstract
Background: Type I interferons (IFNs) are essential antiviral cytokines induced upon respiratory exposure to coronaviruses. Defects in type I IFN signaling can result in severe disease upon exposure to respiratory viral infection and are associated with worse clinical outcomes. Neutralizing autoantibodies (auto‐Abs) to type I IFNs were reported as a risk factor for life‐threatening COVID‐19, but their presence has not been evaluated in patients with severe Middle East respiratory syndrome (MERS). Methods: We evaluated the prevalence of type I IFN auto‐Abs in a cohort of hospitalized patients with MERS who were enrolled in a placebo‐controlled clinical trial for treatment with IFN‐β1b and lopinavir‐ritonavir (MIRACLE trial). Samples were tested for type I IFN auto‐Abs using a multiplex particle‐based assay. Results: Among the 62 enrolled patients, 15 (24.2%) were positive for immunoglobulin G auto‐Abs for at least one subtype of type I IFNs. Auto‐Abs positive patients were not different from auto‐Abs negative patients in age, sex, or comorbidities. However, the majority (93.3%) of patients who were auto‐Abs positive were critically ill and admitted to the ICU at the time of enrollment compared to 66% in the auto‐Abs negative patients. The effect of treatment with IFN‐β1b and lopinavir‐ritonavir did not significantly differ between the two groups. Conclusion: This study demonstrates the presence of type I IFN auto‐Abs in hospitalized patients with MERS. [ABSTRACT FROM AUTHOR]